Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dose determinants of rebound insomnia.

T A Roehrs, F J Zorick, R M Wittig

    British Journal of Clinical Pharmacology
    |August 1, 1986
    PubMed
    Summary

    Rebound insomnia, a sleep disturbance after discontinuing medication, occurred at a higher dose of triazolam (0.50 mg) but not a lower dose (0.25 mg) in healthy sleepers. This higher dose did not offer additional sleep benefits.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Functional host-specific adaptation of the intestinal microbiome in hominids.

    Nature communications·2024
    Same author

    24&#x2003;Evaluation of an antibody-free approach to identifying faecal peptides for pregnancy detection in polar bears (<i>Ursus maritimus</i>).

    Reproduction, fertility, and development·2022
    Same author

    Stratigraphy of stable isotope ratios and leaf structure within an African rainforest canopy with implications for primate isotope ecology.

    Scientific reports·2021
    Same author

    Materials Imaging and Dynamics (MID) instrument at the European X-ray Free-Electron Laser Facility.

    Journal of synchrotron radiation·2021
    Same author

    Efficacy of piperacillin in combination with novel β-lactamase inhibitor IID572 against β-lactamase-producing strains of Enterobacteriaceae and Staphylococcus aureus in murine neutropenic thigh infection models.

    The Journal of antimicrobial chemotherapy·2020
    Same author

    Cortisol and oxytocin show independent activity during chimpanzee intergroup conflict.

    Psychoneuroendocrinology·2019

    Area of Science:

    • Sleep Medicine
    • Pharmacology

    Background:

    • Rebound insomnia is a potential adverse effect following the cessation of hypnotic medications.
    • Understanding dose-dependent relationships is crucial for safe prescribing practices.

    Purpose of the Study:

    • To assess the dose-related effects of triazolam on rebound insomnia in healthy individuals.
    • To evaluate the utility of sleep/wake tendency tests in measuring rebound insomnia.

    Main Methods:

    • Polysomnography was used to assess sleep patterns in 12 healthy men (21-30 years).
    • Participants received placebo, 0.25 mg, and 0.50 mg of triazolam for 6 nights, followed by a discontinuation night.
    • A double-blind, Latin square design was employed.

    Main Results:

    • Both triazolam doses increased total sleep time compared to placebo on night 6.
    • The 0.50 mg dose of triazolam significantly increased wake time and sleep latency on the discontinuation night (night 7) compared to placebo and 0.25 mg.
    • The 0.25 mg dose did not show significant rebound effects compared to placebo.

    Conclusions:

    • Rebound insomnia was observed only at the higher triazolam dose (0.50 mg), which did not provide additional hypnotic efficacy in healthy sleepers.
    • Further research is needed to clarify the usefulness of sleep/wake tendency tests for rebound insomnia assessment.

    Related Experiment Videos